Search for "five-membered rings" in Full Text gives 48 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2017, 13, 1456–1462, doi:10.3762/bjoc.13.143
Graphical Abstract
Scheme 1: Photo-Meerwein reaction leading to amides.
Figure 1: Products detected in the reaction mixtures during attempts to intercept the radical/cationic interm...
Scheme 2: Reaction of o-alkoxycarbonyldiazonium salts with alkenes under Ru-photocatalyzed conditions.
Scheme 3: Proposed mechanism for the reaction of diazonium salt 2h with methyl methacrylate (3a).
Scheme 4: Reaction of 2-aminocarbonyldiazonium salt 2i with styrene (3b).
Figure 2: The meso-flow apparatus assembled in-house. The components are shown on the left, while the operati...
Scheme 5: Reaction of diazonium salts 11 with styrenes 12. The nucleophilic attack to intermediate A is given...
Scheme 6: Proposed mechanism for the formation of benzo[e][1,3]oxazepin-1(5H)-one 14.
Scheme 7: Investigation of the selectivity of the photochemically induced cyclization.
Beilstein J. Org. Chem. 2016, 12, 1870–1876, doi:10.3762/bjoc.12.176
Graphical Abstract
Figure 1: Structure of guanidines 1–10.
Scheme 1: Synthesis of guanidine 10. Conditions: (a) 1 equiv HOOC-CH2-COOH, 2 equiv NH4OAc, EtOH, 78 °C, 5 h,...
Figure 2: Crystal structure of guanidine 10 as a benzoate salt. Only one of the ion pairs is shown for the sa...
Scheme 2: Reaction of anthrones and N-arylmaleimides catalyzed by guanidine 10. The guanidine deprotonates an...
Figure 3: A) Chromatogram of rac-25 after incubation with 0.1 equiv of 10 in THF at −15 °C for 64 h. The fast...
Scheme 3: Assignment of the absolute configurations by chemical correlation. The R configuration of compound ...
Beilstein J. Org. Chem. 2016, 12, 1178–1184, doi:10.3762/bjoc.12.113
Graphical Abstract
Scheme 1: Bromine adducts (trans-1 and cis-1) of 1,1-dimethylindene (2) and their envelope conformations: ax ...
Scheme 2: The ways to 2-bromo- (4), 3-bromo- (3), and 2,3-dibromo-1,1-dimethylindene (7); SuIm = succinimide,...
Scheme 3: Unsolvated 2-bromo-3-lithio-1,1-dimethylindene (10) precipitated from the reaction mixture of 7 wit...
Beilstein J. Org. Chem. 2015, 11, 2727–2736, doi:10.3762/bjoc.11.294
Graphical Abstract
Scheme 1: Schematic view of the calculated carbenes 1–15.
Figure 1: Optimized geometries of carbenes 1–15 at the BP86/def2-TZVPP level of theory. Bond lengths and angl...
Figure 2: Frontier orbitals (BP86/def2-TZVPP) and eigenvalues (in eV) of the carbenes 1–15. The isosurfaces w...
Scheme 2: Schematic view of the major orbital interactions between a carbon atom in the 3P electronic ground ...
Figure 3: Plot of deformation densities ∆ρ of the pairwise orbital interactions between C(3P) and N(Me)HC=CHN...
Figure 4: Plot of the ΔEπ values against NBO pπ occupation for the NHC family 1–15.
Beilstein J. Org. Chem. 2015, 11, 860–868, doi:10.3762/bjoc.11.96
Graphical Abstract
Figure 1: Molecular structures of tetrathiafulvalenes 1, bis-pyrrolotetrathiafulvalenes 2 and monopyrrolotetr...
Scheme 1: The two synthetic approaches used for the preparation of arylated monopyrrolotetrathiafulvalenes 1.
Scheme 2: Synthesis of arylated monopyrrolotetrathiafulvalenes 4a–f.
Figure 2: Copper(I) ligands 9a and 9b.
Figure 3: UV–vis spectra of compounds 4a,c–f (CH2Cl2, c = 4 × 10−5 M).
Figure 4: Cyclic voltammograms of compounds 4a,c [22] and 4d–f (plotted vs SCE; CH2Cl2/0.1 M Bu4NClO4).
Figure 5: Crystal packing of 4a viewed along the a axis and showing one layer of molecules. Short S···S conta...
Figure 6: Crystal packing of 4b showing a group of four molecules interconnected by multiple weak hydrogen bo...
Figure 7: Crystal packing of 4d viewed along the b axis. Molecules of 4d form layers parallel to the (001) pl...
Figure 8: Crystal packing of 4e showing a group of four molecules interconnected by multiple weak hydrogen bo...
Beilstein J. Org. Chem. 2015, 11, 363–372, doi:10.3762/bjoc.11.42
Graphical Abstract
Scheme 1: From indigo to heteroindigo derivatives and all-carbon-indigo.
Scheme 2: Attempts to prepare the α-methylene ketones 12 and 13.
Figure 1: a) Both independent molecules of compound 13 in the crystal; ellipsoids represent 50% probability l...
Scheme 3: Dimerization of 13 under McMurry conditions.
Figure 2: a) The molecule of compound 17 in the crystal; ellipsoids represent 50% probability levels. Only th...
Scheme 4: Dimerization of indan-1-one (18) by a stepwise approach.
Scheme 5: Methylenation of 19 and bisalkylation of the product 23 with 1,2-dibromoethane.
Figure 3: The molecule of compound 23 in the crystal. Ellipsoids represent 50% probability levels. Only the a...
Figure 4: a) The molecule of compound 24 in the crystal. Ellipsoids represent 50% probability levels. Only th...
Figure 5: One of the two independent molecules of compound 25 in the crystal. Ellipsoids represent 50% probab...
Scheme 6: Cross-conjugated hydrocarbons by Thiele condensation.
Figure 6: a) The molecule of compound 30 in the crystal. Ellipsoids represent 50% probability levels. Only th...
Beilstein J. Org. Chem. 2015, 11, 313–322, doi:10.3762/bjoc.11.36
Graphical Abstract
Scheme 1: Fenchyl-based ligands used as building blocks for phosphorous ligands or organoaluminum reagents.
Scheme 2: Reaction of BIFOP–Cl (1) to BIFOP–(O)H (2) and of O–BIFOP–Cl (3) yielding O–BIFOP–H (4), O–BIFOP–(O...
Figure 1: 31P NMR (125 MHz, CDCl3) of O–BIFOP–Cl (3, δ = 161.9) after the addition of 1 equiv H2O and formati...
Figure 2: X-ray crystal structure of diphenyl ether-2,2’-biscyclofenchene 7. Ellipsoids are shown with 50% pr...
Scheme 3: Proposed mechanism for the formation of diphenyl ether-2,2’-biscyclofenchene 7 through stabilizatio...
Figure 3: 31P NMR (125 MHz, CDCl3) of O–BIFOP–H (4, δ = 152.5) adding O2 after a) 5 min; b) 15 min; c) 120 mi...
Figure 4: X-ray crystal structure of BIFOP-Cl 1. Ellipsoids are shown with 50% probability [15].
Scheme 4: The different backbones provoke different reactivities due to tighter encapsulation of the P–Cl uni...
Figure 5: X-ray crystal structure of O-BIFOP-Cl (3). Ellipsoids are shown with 50% probability.
Figure 6: Transition state structure for the reaction of BIFOP–Cl (1) with water (BP86/def-SV(P)).
Figure 7: Transition state structure for the reaction of O-BIFOP–Cl (3) with water (BP86/def-SV(P)).
Beilstein J. Org. Chem. 2015, 11, 265–270, doi:10.3762/bjoc.11.29
Graphical Abstract
Figure 1: Hyperaspidinols A (1) and B (2) and other compounds 3-6 from Hypericum chinense.
Figure 2: Hyperaspidinol A (1), target compound 7 and proposed precursors.
Scheme 1: Reagents and conditions: (i) triethylphosphonoacetate, DBU, THF, 48 h, 94%; (ii) H2, 10% Pd/C, EtOA...
Scheme 2: Reagents and conditions: (i) H3C(CH3O)NH·HCl, n-BuLi, THF, −78 °C, 4 h, 81%; (ii) 1-bromo-3,4-methy...
Figure 3: NOESY correlations in isomers 7a and 7b.
Figure 4: 3D representation of 7a.
Figure 5: 3D representation of 7b.
Figure 6: Possible mechanism for the formation of furo[2,3-b]chromenes 7a and 7b.
Beilstein J. Org. Chem. 2014, 10, 2021–2026, doi:10.3762/bjoc.10.210
Graphical Abstract
Scheme 1: [2.2]Paracyclophane derivatives with annelated alicyclic rings.
Scheme 2: The formation of the tetraketone 9 by a Diels–Alder addition.
Scheme 3: The possible structures of the aldols formed from 9.
Figure 1: Structure of 12·CDCl3 in the crystal. Ellipsoids represent 50% probability levels. Selected bond le...
Scheme 4: The mechanism of the aldol cyclization.
Scheme 5: Dehydration of the aldol 12.
Scheme 6: Dehydration of the aldol 15.
Figure 2: Structure of compound 21 in the crystal. Ellipsoids represent 50% probability levels. Selected bond...
Beilstein J. Org. Chem. 2014, 10, 544–598, doi:10.3762/bjoc.10.50
Graphical Abstract
Scheme 1: The proposed mechanism of the Passerini reaction.
Scheme 2: The PADAM-strategy to α-hydroxy-β-amino amide derivatives 7. An additional oxidation provides α-ket...
Scheme 3: The general accepted Ugi-mechanism.
Scheme 4: Three commonly applied Ugi/cyclization approaches. a) UDC-process, b) UAC-sequence, c) UDAC-combina...
Scheme 5: Ugi reaction that involves the condensation of Armstrong’s convertible isocyanide.
Scheme 6: Mechanism of the U-4C-3CR towards bicyclic β-lactams.
Scheme 7: The Ugi 4C-3CR towards oxabicyclo β-lactams.
Scheme 8: Ugi MCR between an enantiopure monoterpene based β-amino acid, aldehyde and isocyanide resulting in...
Scheme 9: General MCR for β-lactams in water.
Scheme 10: a) Ugi reaction for β-lactam-linked peptidomimetics. b) Varying the β-amino acid resulted in β-lact...
Scheme 11: Ugi-4CR followed by a Pd-catalyzed Sn2 cyclization.
Scheme 12: Ugi-3CR of dipeptide mimics from 2-substituted pyrrolines.
Scheme 13: Joullié–Ugi reaction towards 2,5-disubstituted pyrrolidines.
Scheme 14: Further elaboration of the Ugi-scaffold towards bicyclic systems.
Scheme 15: Dihydroxyproline derivatives from an Ugi reaction.
Scheme 16: Diastereoselective Ugi reaction described by Banfi and co-workers.
Scheme 17: Similar Ugi reaction as in Scheme 16 but with different acids and two chiral isocyanides.
Scheme 18: Highly diastereoselective synthesis of pyrrolidine-dipeptoids via a MAO-N/MCR-procedure.
Scheme 19: MAO-N/MCR-approach towards the hepatitis C drug telaprevir.
Scheme 20: Enantioselective MAO-U-3CR procedure starting from chiral pyrroline 64.
Scheme 21: Synthesis of γ-lactams via an UDC-sequence.
Scheme 22: Utilizing bifunctional groups to provide bicyclic γ-lactam-ketopiperazines.
Scheme 23: The Ugi reaction provided both γ- as δ-lactams depending on which inputs were used.
Scheme 24: The sequential Ugi/RCM with olefinic substrates provided bicyclic lactams.
Scheme 25: a) The structural and dipole similarities of the triazole unit with the amide bond. b) The copper-c...
Scheme 26: The Ugi/Click sequence provided triazole based peptidomimetics.
Scheme 27: The Ugi/Click reaction as described by Nanajdenko.
Scheme 28: The Ugi/Click-approach by Pramitha and Bahulayan.
Scheme 29: The Ugi/Click-combination by Niu et al.
Scheme 30: Triazole linked peptidomimetics obtained from two separate MCRs and a sequential Click reaction.
Scheme 31: Copper-free synthesis of triazoles via two MCRs in one-pot.
Scheme 32: The sequential Ugi/Paal–Knorr reaction to afford pyrazoles.
Scheme 33: An intramolecular Paal–Knorr condensation provided under basic conditions pyrazolones.
Scheme 34: Similar cyclization performed under acidic conditions provided pyrazolones without the trifluoroace...
Scheme 35: The Ugi-4CR towards 2,4-disubstituted thiazoles.
Scheme 36: Solid phase approach towards thiazoles.
Scheme 37: Reaction mechanism of formation of thiazole peptidomimetics containing an additional β-lactam moiet...
Scheme 38: The synthesis of the trisubstituted thiazoles could be either performed via an Ugi reaction with pr...
Scheme 39: Performing the Ugi reaction with DMB-protected isocyanide gave access to either oxazoles or thiazol...
Scheme 40: Ugi/cyclization-approach towards 2,5-disubstituted thiazoles. The Ugi reaction was performed with d...
Scheme 41: Further derivatization of the thiazole scaffold.
Scheme 42: Three-step procedure towards the natural product bacillamide C.
Scheme 43: Ugi-4CR to oxazoles reported by Zhu and co-workers.
Scheme 44: Ugi-based synthesis of oxazole-containing peptidomimetics.
Scheme 45: TMNS3 based Ugi reaction for peptidomimics containing a tetrazole.
Scheme 46: Catalytic cycle of the enantioselective Passerini reaction towards tetrazole-based peptidomimetics.
Scheme 47: Tetrazole-based peptidomimetics via an Ugi reaction and a subsequent sigmatropic rearrangement.
Scheme 48: Resin-bound Ugi-approach towards tetrazole-based peptidomimetics.
Scheme 49: Ugi/cyclization approach towards γ/δ/ε-lactam tetrazoles.
Scheme 50: Ugi-3CR to pipecolic acid-based peptidomimetics.
Scheme 51: Staudinger–Aza-Wittig/Ugi-approach towards pipecolic acid peptidomimetics.
Figure 1: The three structural isomers of diketopiperazines. The 2,5-DKP isomer is most common.
Scheme 52: UDC-approach to obtain 2,5-DKPs, either using Armstrong’s isocyanide or via ethylglyoxalate.
Scheme 53: a) Ugi reaction in water gave either 2,5-DKP structures or spiro compounds. b) The Ugi reaction in ...
Scheme 54: Solid-phase approach towards diketopiperazines.
Scheme 55: UDAC-approach towards DKPs.
Scheme 56: The intermediate amide is activated as leaving group by acid and microwave assisted organic synthes...
Scheme 57: UDC-procedure towards active oxytocin inhibitors.
Scheme 58: An improved stereoselective MCR-approach towards the oxytocin inhibitor.
Scheme 59: The less common Ugi reaction towards DKPs, involving a Sn2-substitution.
Figure 2: Spatial similarities between a natural β-turn conformation and a DKP based β-turn mimetic [158].
Scheme 60: Ugi-based syntheses of bicyclic DKPs. The amine component is derived from a coupling between (R)-N-...
Scheme 61: Ugi-based synthesis of β-turn and γ-turn mimetics.
Figure 3: Isocyanide substituted 3,4-dihydropyridin-2-ones, dihydropyridines and the Freidinger lactams. Bio-...
Scheme 62: The mechanism of the 4-CR towards 3,4-dihydropyridine-2-ones 212.
Scheme 63: a) Multiple MCR-approach to provide DHP-peptidomimetic in two-steps. b) A one-pot 6-CR providing th...
Scheme 64: The MCR–alkylation–MCR procedure to obtain either tetrapeptoids or depsipeptides.
Scheme 65: U-3CR/cyclization employing semicarbazone as imine component gave triazine based peptidomimetics.
Scheme 66: 4CR towards triazinane-diones.
Scheme 67: The MCR–alkylation–IMCR-sequence described by our group towards triazinane dione-based peptidomimet...
Scheme 68: Ugi-4CR approaches followed by a cyclization to thiomorpholin-ones (a) and pyrrolidines (b).
Scheme 69: UDC-approach for benzodiazepinones.
Scheme 70: Ugi/Mitsunobu sequence to BDPs.
Scheme 71: A UDAC-approach to BDPs with convertible isocyanides. The corresponding amide is cleaved by microwa...
Scheme 72: microwave assisted post condensation Ugi reaction.
Scheme 73: Benzodiazepinones synthesized via the post-condensation Ugi/ Staudinger–Aza-Wittig cyclization.
Scheme 74: Two Ugi/cyclization approaches utilizing chiral carboxylic acids. Reaction (a) provided the product...
Scheme 75: The mechanism of the Gewald-3CR includes three base-catalysed steps involving first a Knoevnagel–Co...
Scheme 76: Two structural 1,4-thienodiazepine-2,5-dione isomers by U-4CR/cyclization.
Scheme 77: Tetrazole-based diazepinones by UDC-procedure.
Scheme 78: Tetrazole-based BDPs via a sequential Ugi/hydrolysis/coupling.
Scheme 79: MCR synthesis of three different tricyclic BPDs.
Scheme 80: Two similar approaches both involving an Ugi reaction and a Mitsunobu cyclization.
Scheme 81: Mitsunobu–Ugi-approach towards dihydro-1,4-benzoxazepines.
Scheme 82: Ugi reaction towards hetero-aryl fused 5-oxo-1,4-oxazepines.
Scheme 83: a) Ugi/RCM-approach towards nine-membered peptidomimetics b) Sequential peptide-coupling, deprotect...
Scheme 84: Ugi-based synthesis towards cyclic RGD-pentapeptides.
Scheme 85: Ugi/MCR-approach towards 12–15 membered macrocycles.
Scheme 86: Stereoselective Ugi/RCM approach towards 16-membered macrocycles.
Scheme 87: Passerini/RCM-sequence to 22-membered macrocycles.
Scheme 88: UDAC-approach towards 12–18-membered depsipeptides.
Figure 4: Enopeptin A with its more active derivative ADEP-4.
Scheme 89: a) The Joullié–Ugi-approach towards ADEP-4 derivatives b) Ugi-approach for the α,α-dimethylated der...
Scheme 90: Ugi–Click-strategy for 15-membered macrocyclic glyco-peptidomimetics.
Scheme 91: Ugi/Click combinations provided macrocycles containing both a triazole and an oxazole moiety.
Scheme 92: a) A solution-phase procedure towards macrocycles. b) Alternative solid-phase synthesis as was repo...
Scheme 93: Ugi/cyclization towards cyclophane based macrocycles.
Scheme 94: PADAM-strategy towards eurystatin A.
Scheme 95: PADAM-approach for cyclotheanamide.
Scheme 96: A triple MCR-approach affording RGD-pentapeptoids.
Scheme 97: Ugi-MiBs-approach towards peptoid macrocycles.
Scheme 98: Passerini-based MiB approaches towards macrocycles 345 and 346.
Scheme 99: Macrocyclic peptide formation by the use of amphoteric aziridine-based aldehydes.
Beilstein J. Org. Chem. 2014, 10, 271–275, doi:10.3762/bjoc.10.22
Graphical Abstract
Scheme 1: Reaction scheme for the preparation of cyclic phosphonium ionic liquids.
Beilstein J. Org. Chem. 2013, 9, 2696–2708, doi:10.3762/bjoc.9.306
Graphical Abstract
Figure 1: Fluorination alters the reactivity of aziridines.
Scheme 1: Fluorination makes β-lactam derivatives more reactive towards lipase-catalysed methanolysis.
Figure 2: The ring pucker in azetidine derivatives can be influenced by a C–F…N+ charge–dipole interaction.
Figure 3: Fluorination ridifies the pyrrolidine rings of ligand 10, with several consequences for its G-quadr...
Figure 4: Proline 11 readily undergoes a ring-flip process, but (4R)-fluoroproline 12 is more rigid because o...
Scheme 2: Hyperconjugation rigidifies the ring pucker of a fluorinated organocatalyst 14, leading to higher e...
Figure 5: Fluorinated piperidines prefer the axial conformation, due to stabilising C–F…N+ interactions.
Figure 6: Fluorination can rigidify a substituted azepane, but only if it acts in synergy with the other subs...
Figure 7: The eight-membered N-heterocycle 24 prefers an axial orientation of the fluorine substituent, givin...
Figure 8: Some iminosugars are “privileged structures” that serve as valuable drug leads.
Figure 9: Fluorinated iminosugar analogues 32–34 illuminate the binding interactions of the α-glycosidase inh...
Figure 10: Fluorinated miglitol analogues, and their inhibitory activity towards yeast α-glycosidase.
Figure 11: Analogues of isofagomine (31) have different pKaH values, and therefore exhibit maximal β-glucosida...
Scheme 3: General strategy for the synthesis of fluorinated N-heterocycles via deoxyfluorination.
Figure 12: Late stage deoxyfluorination in the synthesis of multifunctional N-heterocycles.
Scheme 4: During the deoxyfluorination of N-heterocycles, neighbouring group participation can sometimes lead...
Scheme 5: A building block approach for the synthesis of fluorinated aziridines 2 and 3.
Scheme 6: Building block approach for the synthesis of a difluorinated analogue of calystegine B (63).
Scheme 7: Synthesis of fluorinated analogues of brevianamide E (65) and gypsetin (68) via electrophilic fluor...
Scheme 8: Organocatalysed enantioselective fluorocyclisation.
Scheme 9: Synthesis of 3-fluoroazetidine 73 via radical fluorination.
Scheme 10: Synthesis of 3,3-difluoropyrrolidine 78 via a radical cyclisation.
Scheme 11: Chemoenzymatic synthesis of fluorinated β-lactam 4b.
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 1668–1676, doi:10.3762/bjoc.9.191
Graphical Abstract
Figure 1: Formal, topological approach to derive coarctate reactions from pericyclic reactions; p, q: number ...
Figure 2: Stereochemistry of coarctate reactions derived from a Hückel (top) and a Möbius band (bottom). The ...
Scheme 1: Coarctate fragmentation of the spiroozonide derived from methylenecyclopropane.
Scheme 2: Photochemically and thermally allowed coarctate fragmentations of spiroketals.
Scheme 3: Precursors used in this study.
Figure 3: Difference infrared spectrum, showing the changes in the IR spectrum after photolysis (λexc = 254 n...
Figure 4: Infrared spectrum obtained upon FVP of 1 at T = 1143 K and trapping the pyrolysate in solid argon a...
Figure 5: Infrared spectrum obtained upon FVP of 2 at T = 963 K and trapping the pyrolysate in solid argon at ...
Figure 6: Infrared spectrum obtained upon FVP of 3 at T = 1043 K and trapping the pyrolysate in solid argon a...
Scheme 4: Possible fragmentation pathways in the FVP of 1.
Scheme 5: Possible fragmentation pathways in the FVP of 2.
Scheme 6: Possible fragmentation pathways in the FVP of 3.
Beilstein J. Org. Chem. 2013, 9, 1127–1134, doi:10.3762/bjoc.9.125
Graphical Abstract
Figure 1: 2- and 4-fluorophenylboronic acids (1 and 2) and 2-substituted phenylboranes [X = F (3), Cl (4), Br...
Figure 2: Molecular graphs for the energy minima of 2- and 4-fluorophenylboronic acids. Green dots represent ...
Figure 3: Important hyperconjugative interactions for 1a (from the left to the right: nF→σ*OH, nF→π*CC and πCC...
Figure 4: Infrared spectrum of 2-fluorophenylboronic acid in 0.1 M chloroform solution.
Figure 5: 1H NMR spectrum for 1 in (a) C6D6 solution (2 mg mL−1) and (b) CD3CN solution (20 mg mL−1).
Figure 6: Angular dependence of 1hJF,H(O) and nF→σ*OH in 1a, obtained at the BHandH/EPR-III (J) and B3LYP/aug...
Figure 7: Molecular graphs indicating bond paths (BPs), bond critical points (BCPs; green dots), and ring cri...
Beilstein J. Org. Chem. 2013, 9, 557–576, doi:10.3762/bjoc.9.61
Graphical Abstract
Scheme 1: Key radical step in the total synthesis of (–)-dendrobine.
Scheme 2: Radical cascade in the total synthesis of (±)-13-deoxyserratine (ACCN = 1,1'-azobis(cyclohexanecarb...
Scheme 3: Formation of the complete skeleton of (±)-fortucine.
Scheme 4: Model radical sequence for the synthesis of quadrone.
Scheme 5: Radical cascade using the Barton decarboxylation.
Scheme 6: Simplified mechanism for the xanthate addition to alkenes.
Scheme 7: Synthesis of β-lactam derivatives.
Scheme 8: Sequential additions to three different alkenes (PhthN = phthalimido).
Scheme 9: Key cascade in the total synthesis of (±)-matrine (43).
Scheme 10: Synthesis of complex tetralones.
Scheme 11: Synthesis of functionalised azaindoline and indole derivatives.
Scheme 12: Synthesis of thiochromanones.
Scheme 13: Synthesis of complex benzothiepinones. Conditions: 1) CF3COOH; 2) RCHO / AcOH (PMB = p-methoxybenzy...
Scheme 14: Formation and capture of a cyclic nitrone.
Scheme 15: Synthesis of bicyclic cyclobutane motifs.
Scheme 16: Construction of the CD rings of steroids.
Scheme 17: Rapid assembly of polyquinanes.
Scheme 18: Formation of a polycyclic structure via an allene intermediate.
Scheme 19: A polycyclic structure via the alkylative Birch reduction.
Scheme 20: Synthesis of polycyclic pyrimidines and indoline structures.
Scheme 21: Construction of a trans-decalin derivative.
Scheme 22: Multiple uses of a chloroacetonyl xanthate.
Scheme 23: A convergent route to spiroketals.
Scheme 24: A modular approach to 3-arylpiperidines.
Scheme 25: A convergent route to cyclopentanols and to functional allenes.
Scheme 26: Allylation and vinylation of a xanthate and an iodide.
Scheme 27: Vinyl epoxides as allylating agents.
Scheme 28: Radical allylations using allylic alcohol derivatives.
Scheme 29: Synthesis of variously substituted lactams.
Scheme 30: Nickel-mediated synthesis of unsaturated lactams.
Scheme 31: Total synthesis of (±)-3-demethoxy-erythratidinone.
Scheme 32: Generation and capture of an iminyl radical from an oxime ester.
Beilstein J. Org. Chem. 2013, 9, 313–322, doi:10.3762/bjoc.9.36
Graphical Abstract
Scheme 1: Intermolecular carbolithiation.
Scheme 2: Carbolithiation of cinnamyl and dienyl derivatives.
Scheme 3: Carbolithiation of cinnamyl alcohol.
Scheme 4: Carbolithiation of styrene derivatives.
Scheme 5: Carbolithiation of α-aryl O-alkenyl carbamates.
Scheme 6: Carbolithiation-rearrangement of N-alkenyl-N-arylureas.
Scheme 7: Carbolithiation of N,N-dimethylaminofulvene.
Scheme 8: Carbolithiation of enynes.
Scheme 9: Intramolecular carbolithiation.
Scheme 10: Carbolithiation of 5-alkenylcarbamates.
Scheme 11: Carbolithiation of cinnamylpiperidines.
Scheme 12: Carbolithiation of alkenylpyrrolidines.
Scheme 13: Enantioselective carbolithiation of N-allyl-2-bromoanilines.
Scheme 14: Effect of the ligand in the carbolithiation reaction.
Scheme 15: Effect of the alkene substitution in the carbolithiation reaction.
Scheme 16: Effect of the ring substitution in the carbolithiation reaction.
Scheme 17: Enantioselective carbolithiation of allyl aryl ethers.
Scheme 18: Formation of six-membered rings: pyrroloisoquinolines.
Scheme 19: Formation of six-membered rings: tetrahydroquinolines.
Beilstein J. Org. Chem. 2013, 9, 265–269, doi:10.3762/bjoc.9.32
Graphical Abstract
Figure 1: The structures of azatriquinanes and azatriquinacene.
Figure 2: The synthesis of 4 (previous work).
Scheme 1: The designed synthetic route to a hydroxy NHC from 4b.
Scheme 2: The reduction of amides 4 by LiAlH4 and BH3·THF.
Figure 3: X-ray crystal structure of compound 5a.
Scheme 3: One-pot tandem cyclization of 6 in the presence of HC(OCH3)3.
Figure 4: X-ray crystal structure of compound 7b.
Figure 5: The structural comparison of chiral ammonium salts such as 7 with the chiral PTCs of Denmark et al.
Beilstein J. Org. Chem. 2012, 8, 1936–1998, doi:10.3762/bjoc.8.225
Graphical Abstract
Figure 1: Loschmidt’s structure proposal for benzene (1) (Scheme 181 from [3]) and the corresponding modern stru...
Figure 2: The first isolated bisallenes.
Figure 3: Carbon skeletons of selected bisallenes discussed in this review.
Scheme 1: The preparation of 1,2,4,5-hexatetraene (2).
Scheme 2: The preparation of a conjugated bisallene by the DMS-protocol.
Scheme 3: Preparation of the 3-deuterio- and 3,4-dideuterio derivatives of 24.
Scheme 4: A versatile method to prepare alkylated conjugated bisallenes and other allenes.
Scheme 5: A preparation of 3,4-dimethyl-1,2,4,5-hexatetraene (38).
Scheme 6: A (C6 + 0)-approach to 1,2,4,5-hexatetraene (2).
Scheme 7: The preparation of a fully alkylated bisallenes from a 2,4-hexadiyne-1,6-diol diacetate.
Scheme 8: The preparation of the first phenyl-substituted conjugated bisallenes 3 and 4.
Scheme 9: Selective hydrogenation of [5]cumulenes to conjugated bisallenes: another (C6 + 0)-route.
Scheme 10: Aryl-substituted conjugated bisallenes by a (C3 + C3)-approach.
Scheme 11: Hexaphenyl-1,2,4,5-hexatetraene (59) by a (C3 + C3)-approach.
Scheme 12: An allenation route to conjugated bisallenes.
Scheme 13: The preparation of 3,4-difunctionalized conjugated bisallenes.
Scheme 14: Problems during the preparation of sulfur-substituted conjugated bisallenes.
Scheme 15: The preparation of 3,4-dibromo bisallenes.
Scheme 16: Generation of allenolates by an oxy-Cope rearrangement.
Scheme 17: A linear trimerization of alkynes to conjugated bisallenes: a (C2 + C2 + C2)-protocol.
Scheme 18: Preparation of a TMS-substituted conjugated bisallene by a C3-dimerization route.
Scheme 19: A bis(trimethylsilyl)bisallene by a C3-coupling protocol.
Scheme 20: The rearrangement of highly substituted benzene derivatives into their conjugated bisallenic isomer...
Scheme 21: From fully substituted benzene derivatives to fully substituted bisallenes.
Scheme 22: From a bicyclopropenyl to a conjugated bisallene derivative.
Scheme 23: The conversion of a bismethylenecyclobutene into a conjugated bisallene.
Scheme 24: The preparation of monofunctionalized bisallenes.
Scheme 25: Preparation of bisallene diols and their cyclization to dihydrofurans.
Scheme 26: A 3,4-difunctionalized conjugated bisallene by a C3-coupling process.
Scheme 27: Preparation of a bisallenic diketone by a coupling reaction.
Scheme 28: Sulfur and selenium-substituted bisallenes by a [2.3]sigmatropic rearrangement.
Scheme 29: The biallenylation of azetidinones.
Scheme 30: The preparation of a fully ferrocenylated conjugated bisallene.
Scheme 31: The first isomerization of a 1,5-hexadiyne to a 1,2,4,5-hexatetraene.
Scheme 32: The preparation of alkynyl-substituted bisallenes by a C3-dimerization protocol.
Scheme 33: Preparation of another completely ferrocenylated bisallene.
Scheme 34: The cyclization of 1,5-hexadiyne (129) to 3,4-bismethylenecyclobutene (130) via 1,2,4,5-hexatetraen...
Scheme 35: Stereochemistry of the thermal cyclization of bisallenes to bismethylenecyclobutenes.
Scheme 36: Bisallene→bismethylenecyclobutene ring closures in the solid state.
Scheme 37: A bisallene cyclization/dimerization reaction.
Scheme 38: A selection of Diels–Alder additions of 1,2,4,5-hexatetraene with various double-bond dienophiles.
Scheme 39: The stereochemistry of the [2 + 4] cycloaddition to conjugated bisallenes.
Scheme 40: Preparation of azetidinone derivatives from conjugated bisallenes.
Scheme 41: Cycloaddition of heterodienophiles to a conjugated bisallene.
Scheme 42: Addition of triple-bond dienophiles to conjugated bisallenes.
Scheme 43: Sulfur dioxide addition to conjugated bisallenes.
Scheme 44: The addition of a germylene to a conjugated bisallene.
Scheme 45: Trapping of conjugated bisallenes with phosphinidenes.
Scheme 46: The cyclopropanantion of 1,2,4,5-hexatetraene (2).
Scheme 47: Photochemical reactions involving conjugated bisallenes.
Scheme 48: Base-catalyzed isomerizations of conjugated bisallenes.
Scheme 49: Ionic additions to a conjugated bisallene.
Scheme 50: Oxidation reactions of a conjugated bisallene.
Scheme 51: The mechanism of oxidation of the bisallene 24.
Scheme 52: CuCl-catalyzed cyclization of 1,2,4,5-hexatetraene (2).
Scheme 53: The conversion of conjugated bisallenes into cyclopentenones.
Scheme 54: Oligomerization of a conjugated bisallene by nickel catalysts.
Scheme 55: Generation of 1,2,5,6-heptatetraene (229) as a reaction intermediate.
Scheme 56: The preparation of a stable derivative of 1,2,5,6-heptatetraene.
Scheme 57: A bisallene with a carbonyl group as a spacer element.
Scheme 58: The first preparation of 1,2,6,7-octatetraene (242).
Scheme 59: Preparation of 1,2,6,7-octatetraenes by (C4 + C4)-coupling of enynes.
Scheme 60: Preparation of 1,2,6,7-octatetraenes by (C4 + C4)-coupling of homoallenyl bromides.
Scheme 61: Preparation of 1,2,6,7-octatetraenes by alkylation of propargylic substrates.
Scheme 62: Preparation of two highly functionalized 1,2,6,7-octatetraenes.
Scheme 63: Preparation of several higher α,ω-bisallenes.
Scheme 64: Preparation of different alkyl derivatives of α,ω-bisallenes.
Scheme 65: The preparation of functionalized 1,2,7,8-nonatetraene derivatives.
Scheme 66: Preparation of functionalized α,ω-bisallenes.
Scheme 67: The preparation of an α,ω-bisallene by direct homologation of an α,ω-bisalkyne.
Scheme 68: The gas-phase pyrolysis of 4,4-dimethyl-1,2,5,6-heptatetraene (237).
Scheme 69: Gas-phase pyrolysis of 1,2,6,7-octatetraene (242).
Scheme 70: The cyclopropanation of 1,2,6,7-octatetraene (242).
Scheme 71: Intramolecular cyclization of 1,2,6,7-octatetraene derivatives.
Scheme 72: The gas-phase pyrolysis of 1,2,7,8-nonatetraene (265) and 1,2,8,9-decatetraene (266).
Scheme 73: Rh-catalyzed cyclization of a functionalized 1,2,7,8-nonatetraene.
Scheme 74: A triple cyclization involving two different allenic substrates.
Scheme 75: Bicyclization of keto derivatives of 1,2,7,8-nonatetraene.
Scheme 76: The preparation of complex organic compounds from functionalized bisallenes.
Scheme 77: Cycloisomerization of an α,ω-bisallene containing a C9 tether.
Scheme 78: Organoborane polymers from α,ω-bisallenes.
Scheme 79: Preparation of trans- (337) and cis-1,2,4,6,7-octapentaene (341).
Scheme 80: The preparation of 4-methylene-1,2,5,6-heptatetraene (349).
Scheme 81: The preparation of acetylenic bisallenes.
Scheme 82: The preparation of derivatives of hydrocarbon 351.
Scheme 83: The construction of macrocyclic alleno-acetylenes.
Scheme 84: Preparation and reactions of 4,5-bismethylene-1,2,6,7-octatetraene (365).
Scheme 85: Preparation of 1,2-bis(propadienyl)benzene (370).
Scheme 86: The preparation of 1,4-bis(propadienyl)benzene (376).
Scheme 87: The preparation of aromatic and heteroaromatic bisallenes by metal-mediated coupling reactions.
Scheme 88: Double cyclization of an aromatic bisallene.
Scheme 89: Preparation of an allenic [15]paracyclophane by a ring-closing metathesis reaction of an aromatic α...
Scheme 90: Preparation of a macrocyclic ring system containing 1,4-bis(propadienyl)benzene units.
Scheme 91: Preparation of copolymers from 1,4-bis(propadienyl)benzene (376).
Scheme 92: A boration/copolymerization sequence of an aromatic bisallene and an aromatic bisacetylene.
Scheme 93: Formation of a layered aromatic bisallene.
Figure 4: The first members of the semicyclic bisallene series.
Scheme 94: Preparation of the first bis(vinylidene)cyclobutane derivative.
Scheme 95: Dimerization of strain-activated cumulenes to bis(vinylidene)cyclobutanes.
Scheme 96: Photodimerization of two fully substituted butatrienes in the solid state.
Scheme 97: Preparation of the two parent bis(vinylidene)cyclobutanes.
Scheme 98: The preparation of 1,3-bis(vinylidene)cyclopentane and its thermal isomerization.
Scheme 99: The preparation of the isomeric bis(vinylidene)cyclohexanes.
Scheme 100: Bi- and tricyclic conjugated bisallenes.
Scheme 101: A selection of polycyclic bisallenes.
Scheme 102: The first endocyclic bisallenes.
Figure 5: The stereochemistry of 1,2,6,7-cyclodecatetraene.
Scheme 103: The preparation of several endocyclic bisallenes.
Scheme 104: Synthesis of diastereomeric derivatives of 1,2,6,7-cyclodecatetraene.
Scheme 105: Preparation of a derivative of 1,2,8,9-cyclotetradecatetraene.
Scheme 106: The preparation of keto derivatives of cyclic bisallenes.
Scheme 107: The preparation of cyclic biscumulenic ring systems.
Scheme 108: Cyclic bisallenes in natural- and non-natural-product chemistry.
Scheme 109: The preparation of iron carbonyl complexes from cyclic bisallenes.
Figure 6: A selection of unknown exocyclic bisallenes that should have interesting chemical properties.
Scheme 110: The thermal isomerization of 1,2-diethynylcyclopropanes and -cyclobutanes.
Scheme 111: Intermediate generation of a cyclooctapentaene.
Scheme 112: Attempted preparation of a cyclodecahexaene.
Scheme 113: The thermal isomerization of 1,5,9-cyclododecatriyne (511) into [6]radialene (514).
Scheme 114: An isomerization involving a diketone derived from a conjugated bisallene.
Scheme 115: Typical reaction modes of heteroorganic bisallenes.
Scheme 116: Generation and thermal behavior of acyclic hetero-organic bisallenes.
Scheme 117: Generation of bis(propadienyl)thioether.
Scheme 118: The preparation of a bisallenic sulfone and its thermal isomerization.
Scheme 119: Bromination of the bisallenic sulfone 535.
Scheme 120: Metalation/hydrolysis of the bisallenic sulfone 535.
Scheme 121: Aromatic compounds from hetero bisallenes.
Scheme 122: Isomerization/cyclization of bispropargylic ethers.
Scheme 123: The preparation of novel aromatic systems by base-catalyzed isomerization of bispropargyl ethers.
Scheme 124: The isomerization of bisacetylenic thioethers to bicyclic thiophenes.
Scheme 125: Aromatization of macrocyclic bispropargylic sulfides.
Scheme 126: Preparation of ansa-compounds from macrocyclic bispropargyl thioethers.
Scheme 127: Alternate route for cyclization of a heterorganic bisallene.
Scheme 128: Multiple isomerization/cyclization of “double” bispropargylic thioethers.
Scheme 129: Preparation of a bisallenyl disulfide and its subsequent bicyclization.
Scheme 130: Thermal cyclization of a bisallenyl thiosulfonate.
Scheme 131: Some reactions of heteroorganic bisallenes with two sulfur atoms.
Scheme 132: Further methods for the preparation of heteroorganic bisallenes.
Scheme 133: Cyclization reactions of heteroorganic bisallenes.
Scheme 134: Thermal cycloadditions of bisallenic tertiary amines.
Scheme 135: Cyclization of a bisallenic tertiary amine in the presence of a transition-metal catalyst.
Scheme 136: A Pauson–Khand reaction of a bisallenic ether.
Scheme 137: Formation of a 2:1adduct from two allenic substrates.
Scheme 138: A ring-forming silastannylation of a bisallenic tertiary amine.
Scheme 139: A three-component cyclization involving a heterorganic bisallene.
Scheme 140: Atom-economic construction of a complex organic framework from a heterorganic α,ω-bisallene.
Beilstein J. Org. Chem. 2012, 8, 1920–1928, doi:10.3762/bjoc.8.223
Graphical Abstract
Scheme 1: Previous design of diastereomeric molecules 2 and 3 with switchable chirality starting from achiral...
Scheme 2: General design of asymmetric pentadentate ligands 4 and chiroptically switchable quasi-diastereomer...
Scheme 3: Preparation of imino–carbonyl ligands 13 by desymmetrization of achiral carbonyl–carbonyl ligands 12...
Scheme 4: Preparation of complexes 14a,b and 15 by reactions of ligands 12 with glycine.
Figure 1: Crystallographic structure of complex 14a.
Scheme 5: Oxidation of enolates 16 and formation of complexes 19 and 20.
Figure 2: Crystallographic structure of complex 19.
Beilstein J. Org. Chem. 2011, 7, 615–621, doi:10.3762/bjoc.7.72
Graphical Abstract
Scheme 1: Stereogenic boron in resolved acyclic and cyclic complexes 1–4.
Scheme 2: Synthesis of the racemic boronate–imine complex 8 and boronate–amine complex 10. Reagents and condi...
Figure 1: Solid-state structure of boronate–imine complex 8 (a) and the chosen asymmetric unit of the crystal...
Figure 2: Superposition of the skeletons of boronate complexes 8 (red) and 10 (green).
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2007, 3, No. 43, doi:10.1186/1860-5397-3-43
Graphical Abstract
Scheme 1: Reagents and conditions: (a) DMF, POCl3; (b) piperidine, ethanol, triethylamine; (c) malonodinitril...
Scheme 2: Mechanism for the formation of pyrazolinoquinolizines 6.